短效与长效重组人生长激素对特发性矮小患儿发育情况及不良反应的影响研究  

Study on the Influence of Short-acting and Long-acting Recombinant Human Growth Hormone on the Development and Adverse Reactions of Children with Idiopathic Short Stature

作　　者：林晓虹 Lin Xiaohong(Department of Pediatrics,Yueqing Maternal and Child Health Hospital,Yueqing,Zhejiang 325600)

机构地区：[1]乐清市妇幼保健院儿科,浙江乐清325600

出　　处：《科技与健康》2025年第3期85-88,共4页Technology and Health

摘　　要：分析了短效与长效重组人生长激素(recombinant human growth hormone,rhGH)对特发性矮小(idiopathic short stature,ISS)患儿的影响。选取2021年5月—2023年5月在乐清市妇幼保健院接受治疗的46例ISS患儿为研究对象。随机将患儿分为长效组(n=23,行0.2 mg/kg rhGH皮下注射治疗,每周1次)和短效组(n=23,行0.15 U/kg rhGH皮下注射治疗,每天1次)。结果显示,治疗后,与短效组相比,长效组身高、Ht SDS、GV均更高(P<0.05);治疗后,与短效组相比,长效组BAP、PINP水平更高,β-CTX水平更低(P<0.05);治疗后,与短效组相比,长效组IGFBP-3、IGF-1水平更高(P<0.05);两组患儿的不良反应发生情况比较,无统计学差异(P>0.05)。研究发现,与短效rhGH治疗相比,长效rhGH治疗对ISS患儿生长发育具有更好的促进作用,改善骨代谢的效果更好,还能够提高血清IGFBP-3、IGF-1水平,且治疗安全性较高。This study aims to analyze the influence of short-acting and long-acting recombinant human growth hormone(rhGH)on children with idiopathic short stature(ISS).A total of 46 children with ISS who were treated in Yueqing Maternal and Child Health Hospital from May 2021 to May 2023 were selected as the research subjects.The children were randomly divided into a long-acting group(n=23,treated with subcutaneous injection of 0.2 mg/kg rhGH once a week)and a short-acting group(n=23,treated with subcutaneous injection of 0.15 U/kg rhGH once a day).The results showed that after treatment,the height,Ht SDS,and GV of the long-acting group were higher than those of the short-acting group(P<0.05).After treatment,the levels of BAP and PINP in the long-acting group were higher,and the level ofβ-CTX was lower than those in the short-acting group(P<0.05).After treatment,the levels of IGFBP-3 and IGF-1 in the long-acting group were higher than those in the short-acting group(P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups of children(P>0.05).The study found that compared with the treatment of short-acting rhGH,the treatment of long-acting rhGH has a better promoting effect on the growth and development of children with ISS,has a better effect on improving bone metabolism,can also increase the levels of serum IGFBP-3 and IGF-1,and has a higher treatment safety.

关 键 词：重组人生长激素 特发性矮小 发育情况 不良反应 

分 类 号：R977[医药卫生—药品]